Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer

Breast
  • 42 Downloads

Abstract

Objectives

To evaluate the changes in mammographic density after tamoxifen discontinuation in premenopausal women with oestrogen receptor-positive breast cancers and the underlying factors

Methods

A total of 213 consecutive premenopausal women with breast cancer who received tamoxifen treatment after curative surgery and underwent three mammograms (baseline, after tamoxifen treatment, after tamoxifen discontinuation) were included. Changes in mammographic density after tamoxifen discontinuation were assessed qualitatively (decrease, no change, or increase) by two readers and measured quantitatively by semi-automated software. The association between % density change and clinicopathological factors was evaluated using univariate and multivariate regression analyses.

Results

After tamoxifen discontinuation, a mammographic density increase was observed in 31.9% (68/213, reader 1) to 22.1% (47/213, reader 2) by qualitative assessment, with a mean density increase of 1.8% by quantitative assessment compared to density before tamoxifen discontinuation. In multivariate analysis, younger age (≤ 39 years) and greater % density decline after tamoxifen treatment (≥ 17.0%) were independent factors associated with density change after tamoxifen discontinuation (p < .001 and p = .003, respectively).

Conclusions

Tamoxifen discontinuation was associated with mammographic density change with a mean density increase of 1.8%, which was associated with younger age and greater density change after tamoxifen treatment.

Key Points

• Increased mammographic density after tamoxifen discontinuation can occur in premenopausal women.

• Mean density increase after tamoxifen discontinuation was 1.8%.

• Density increase is associated with age and density decrease after tamoxifen.

Keywords

Breast density Mammography Tamoxifen Receptors, Oestrogen Prognosis 

Notes

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Nariya Cho.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Ethical approval

Institutional review board approval was obtained.

Informed consent

Written informed consent was waived by the institutional review board.

Methodology

• retrospective

• observational

• performed at one institution

References

  1. 1.
    Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784CrossRefGoogle Scholar
  2. 2.
    MacNab MW, Tallarida RJ, Joseph R (1984) An evaluation of tamoxifen as a partial agonist by classical receptor theory–an explanation of the dual action of tamoxifen. Eur J Pharmacol 103:321–326CrossRefPubMedGoogle Scholar
  3. 3.
    Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075CrossRefPubMedGoogle Scholar
  4. 4.
    Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116:561–570CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cuzick J, Warwick J, Pinney E et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103:744–752CrossRefPubMedGoogle Scholar
  6. 6.
    Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P (2013) Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 31:2249–2256CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kim J, Han W, Moon HG et al (2012) Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 14:R102CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ko KL, Shin IS, You JY, Jung SY, Ro J, Lee ES (2013) Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Res Treat 142:559–567CrossRefPubMedGoogle Scholar
  9. 9.
    Sandberg ME, Li J, Hall P et al (2013) Change of mammographic density predicts the risk of contralateral breast cancer–a case-control study. Breast Cancer Res 15:R57CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nyante SJ, Sherman ME, Pfeiffer RM et al (2015) Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst 107Google Scholar
  11. 11.
    Slanetz PJ, Grandpre LE, Yeh ED, Kopans DB, Mendel JB (2004) Effect of tamoxifen on breast tissue density in premenopausal breast cancer. Breast J 10:27–32CrossRefPubMedGoogle Scholar
  12. 12.
    Byng JW, Yaffe MJ, Jong RA et al (1998) Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 18:1587–1598CrossRefPubMedGoogle Scholar
  13. 13.
    Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L (1995) Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 196:433–437CrossRefPubMedGoogle Scholar
  14. 14.
    McTiernan A, Chlebowski RT, Martin C et al (2009) Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 27:6135–6143CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S (2001) Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285:171–176CrossRefPubMedGoogle Scholar
  16. 16.
    Sterns EE, Zee B (2000) Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable? Breast Cancer Res Treat 59:125–132CrossRefPubMedGoogle Scholar
  17. 17.
    Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE (1990) Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 174:487–490CrossRefPubMedGoogle Scholar
  18. 18.
    Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621–628CrossRefPubMedGoogle Scholar
  19. 19.
    Peyrade F, Frenay M, Etienne MC et al (1996) Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59:401–410CrossRefPubMedGoogle Scholar
  20. 20.
    Kim JY, Cho N, Jeyanth JX et al (2014) Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy. AJR Am J Roentgenol 202:912–921CrossRefPubMedGoogle Scholar
  21. 21.
    Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ko SY, Kim EK, Kim MJ, Moon HJ (2014) Mammographic density estimation with automated volumetric breast density measurement. Korean J Radiol 15:313–321CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© European Society of Radiology 2018

Authors and Affiliations

  1. 1.Department of RadiologySeoul National University HospitalSeoulRepublic of Korea
  2. 2.Department of RadiologyKyungpook National University Chilgok HospitalDaeguRepublic of Korea
  3. 3.Department of RadiologySeoul National College of MedicineSeoulRepublic of Korea
  4. 4.Institute of Radiation MedicineSeoul National University Medical Research CenterSeoulRepublic of Korea
  5. 5.Department of Radiology, College of MedicineYeungnam UniversityDaeguRepublic of Korea
  6. 6.Department of RadiologyGangnam Healthcare CenterSeoulRepublic of Korea

Personalised recommendations